Ovid asks USPTO to review Marinus’ patent around treatment of serious seizure condition

Ovid Ther­a­peu­tics is ramp­ing up its patent fight with Mar­i­nus Phar­ma­ceu­ti­cals.

The ri­val biotechs have been bat­tling for more than a year over patent claims cov­er­ing treat­ment meth­ods for epilep­tic dis­or­ders, in­clud­ing a dif­fi­cult-to-treat con­di­tion char­ac­ter­ized by long-last­ing seizures called sta­tus epilep­ti­cus (SE). On Tues­day, Ovid filed a new pe­ti­tion urg­ing the US Patent and Trade­mark Of­fice (USP­TO) to re­view Mar­i­nus’ Patent No. 11,110,100, which cov­ers meth­ods for ad­min­is­ter­ing Mar­i­nus’ Phase 3 can­di­date ganax­olone to treat SE.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.